IL-10, TGF-?, and glucocorticoid prevent the production of type 2 cytokines in human group 2 innate lymphoid cells - 07/03/18

This research was supported in part by the National Institutes of Health (grant nos. R01 AI104733, R37HL068546, and U19 AI106683) and by grants from the Janssen Research Fund and the Ernest S. Bazley Foundation. |
|
Disclosure of potential conflict of interest: J. A. Poposki's institution received a grant from the National Institutes of Health (NIH) (grant no. R01AI104733) for this work and other works. B. K. Tan's institution received a grant from the NIH (grant no. U19 AI106683) for this work. W. Q. Stevens personally received a grant from Parker B. Francis Fellowship Program, the American Partnership for Eosinophilic Disorders/American Academy of Allergy, Asthma & Immunology (AAAAI) HOPE Pilot Grant Award, and KL-2 Award for this work. L. C. Grammer's institute received a grant and support for travel from the NIH and a grant from Bazley Foundation grant for this work; the institution received grants from the NIH, the Food Allergy Network, and the Bazley Foundation for other works. L. C. Grammer personally received consultancy fees from Astellas Pharmaceuticals; is employed by Northwestern University and Northwestern Medical Faculty Foundation; received payment for lectures from the AAAAI, Mount Sinai, New York, NY; and receives royalties from the AAAAI, Mount Sinai. R. P. Schleimer's institution received a grant from the NIH. R. P. Schleimer personally received consultancy fees from Intersect ENT, GlaxoSmithKline, Allakos, Aurasense, Merck, BioMarck, Sanofi, AstraZeneca/Medimmune, Genentech, Exicure Inc, Otsuka Inc, and Aqualung Therapeutics Corp; received stock options from Allakos, Aurasense, BioMarck, Exicure Inc, and Aqualung Therapeutics Corp. S. S. Smith's institution received Triological Society Career Development Award for this work; she is employed by Northwestern Medicine/Northwestern University. P. Soroosh is employed by Janssen Immunology. O. Akbari's institute received a grant from the NIH for this work. A. Kato's institution received grants from the NIH (grant nos. R01AI104733, U19AI106683, and R37HL068546) and Janssen Research Fund for this work. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 141 - N° 3
P. 1147 - mars 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?